Number of approved drug evaluation applications in China 2021, by type of application
In 2021, the Chinese Center for Drug Evaluation of the National Medical Products Administration (NMPA) approved more than 10,000 drug evaluation applications. Almost a quarter of all approvals were given directly without technical reviews. More than 2,100 approvals were granted to Investigational New Drug (IND) applications, while 323 New Drug Applications (NDA) and more than 1,000 Abbreviated New Drug Applications (ANDA) were approved during the year.